Corrigendum: ACTIVATE-2: A double-blind randomized trial of BCG vaccination against COVID-19 in individuals at risk.

MLA

Tsilika, Maria, et al. “Corrigendum: ACTIVATE-2: A Double-Blind Randomized Trial of BCG Vaccination against COVID-19 in Individuals at Risk.” Frontiers in Immunology, vol. 13, Aug. 2022, p. 1018384. EBSCOhost, https://doi.org/10.3389/fimmu.2022.1018384.

APA

Tsilika, M., Taks, E., Dolianitis, K., Kotsaki, A., Leventogiannis, K., Damoulari, C., Kostoula, M., Paneta, M., Adamis, G., Papanikolaou, I., Stamatelopoulos, K., Bolanou, A., Katsaros, K., Delavinia, C., Perdios, I., Pandi, A., Tsiakos, K., Proios, N., Kalogianni, E., … Giamarellos-Bourboulis, E. J. (2022). Corrigendum: ACTIVATE-2: A double-blind randomized trial of BCG vaccination against COVID-19 in individuals at risk. Frontiers in Immunology, 13, 1018384. https://doi.org/10.3389/fimmu.2022.1018384

Chicago

Tsilika, Maria, Esther Taks, Konstantinos Dolianitis, Antigone Kotsaki, Konstantinos Leventogiannis, Christina Damoulari, Maria Kostoula, et al. 2022. “Corrigendum: ACTIVATE-2: A Double-Blind Randomized Trial of BCG Vaccination against COVID-19 in Individuals at Risk.” Frontiers in Immunology 13 (August): 1018384. doi:10.3389/fimmu.2022.1018384.